April/May #171 : “C” the Future - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Fearing No Evil

The French Connection




Hep C Treatment Transformation

“C” the Future

It’s in the Mail

7 Tips to Get Your Meds on Time

Some Big Facts About the Big C

Cure Watch




Clever Campaigner

Scared Safe?

Hey Mr. DJ

Playing Sex Games

Pozarazzi

Boys Who Like Boys

Rewriting History




Editor's Letter

Letters

Native Son



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

April / May 2011


“C” the Future

by Tim Murphy

Look what else is coming down the pike to go up against hepatitis C.

Protease Inhibitors 

Telaprevir and boceprevir are the first two of this class of drugs that stop hep C from splitting in two in order to reproduce itself. Dozens more  are in development, including Roche’s danoprevir, but so far it looks like resistance to one means resistance to all.

Polymerase Inhibitors
This class (about a dozen are in development, none further along than Phase II clinical trials) also jams a key step in hep C’s viral replication. Some are stronger against resistance than protease inhibitors and are active against more than one hep C genotype. (Of the six major hep C genotypes, type 1 is by far the most common in this country. Telaprevir works against types 1 and 2 but not 3; boceprevir has only been tested against genotype 1.) In the long run, polymerase inhibitors may become the true backbone of hep C treatment.

NS5A Inhibitors

NS5A inhibitors—easier-to-take forms of interferon and immune-based therapies—block a key protein hep C uses to replicate. Immune-based therapies, such as therapeutic vaccines, juice up the body’s own response to hepatitis C. They’re in very early trials, all part of the arsenal of hep C therapies in development. You can follow their progress and cheer them on at poz.com, treatmentactiongroup.org and natap.org.

Click here to read our feature story on this topic.

Search: Protease Inhibitors, Telaprevir, boceprevir, Polymerase Inhibitors, NS5A Inhibitors


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    Loveladyd
    Washington
    DC


    Sexynyrican
    Brooklyn
    New York


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.